STOCK TITAN
  1. Home
  2. Sec-filings
  3. CYTK
  4. [Form 4] CYTOKINETICS INC Insider Trading Activity

Cytokinetics (CYTK) CFO granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cytokinetics EVP and CFO Sung Lee received new equity awards. On 2026-03-15, Lee was granted 20,646 shares of Common Stock as an annual restricted stock unit award, increasing his direct holdings to 92,062 shares. He also received incentive and non-qualified stock options on 1,665 and 29,480 shares at an exercise price of $60.0600, vesting over four years.

Positive

  • None.

Negative

  • None.
Insider Lee Sung
Role EVP, Chief Financial Officer
Type Security Shares Price Value
Grant/Award Incentive Stock Option (Right to Buy) 1,665 $0.00 --
Grant/Award Non-Qualified Stock Option (Right to Buy) 29,480 $0.00 --
Grant/Award Common Stock 20,646 $0.00 --
Holdings After Transaction: Incentive Stock Option (Right to Buy) — 1,665 shares (Direct); Non-Qualified Stock Option (Right to Buy) — 29,480 shares (Direct); Common Stock — 92,062 shares (Direct)
Footnotes (1)
  1. Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lee Sung
(Last) (First) (Middle)
350 OYSTER POINT BLVD
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/15/2026 A(1) 20,646 A $0 92,062 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (Right to Buy) $60.06 03/15/2026 A(2) 1,665 04/15/2026 03/14/2036 Common Stock 1,665 $0 1,665 D
Non-Qualified Stock Option (Right to Buy) $60.06 03/15/2026 A(3) 29,480 04/15/2026 03/14/2036 Common Stock 29,480 $0 29,480 D
Explanation of Responses:
1. Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
2. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
3. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
/s/ John O. Faurescu, attorney-in-fact for Mr. Lee 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Cytokinetics (CYTK) CFO Sung Lee report in this Form 4?

Sung Lee reported annual equity awards in the form of restricted stock units and stock options. He received 20,646 Common Stock RSUs and options on 1,665 and 29,480 shares, all as compensation rather than open-market purchases or sales.

How many Cytokinetics shares does CFO Sung Lee hold after these grants?

After the reported equity grant, Sung Lee directly holds 92,062 shares of Cytokinetics Common Stock. This figure reflects his position following the award of 20,646 new shares that were granted as part of his annual restricted stock unit compensation package.

What are the key terms of Sung Lee’s new stock options at Cytokinetics?

Sung Lee received two stock option grants covering 1,665 and 29,480 shares of Common Stock at an exercise price of $60.0600. These options vest in 48 equal monthly installments and expire on 2036-03-14, subject to continued employment with Cytokinetics.

How do Sung Lee’s new RSUs at Cytokinetics vest over time?

The 20,646 restricted stock units vest based on employment tenure: 40% on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third anniversary, assuming Sung Lee continues working at Cytokinetics throughout this period.

Are Sung Lee’s new Cytokinetics equity awards part of a company plan?

Yes. Both the restricted stock units and stock options are granted under Cytokinetics’ Amended and Restated 2004 Equity Incentive Plan. This plan governs vesting schedules, employment conditions, and other terms affecting how and when these equity awards may be exercised or converted.

Did Sung Lee buy or sell Cytokinetics shares on the market in this filing?

No. The Form 4 only reports equity awards granted as compensation, coded as acquisitions under transaction code “A.” There are no open-market purchases or sales; instead, the filing shows new RSUs and stock options that vest over time, subject to continued employment.